- Home
- IVVD vs ATRA Comparison
IVVD vs ATRA Comparison
Compare IVVD & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVVD
- ATRA
- Stock Information
- Founded
- IVVD 2020
- ATRA 2012
- Country
- IVVD United States
- ATRA United States
- Employees
- IVVD N/A
- ATRA N/A
- Industry
- IVVD Biotechnology: Pharmaceutical Preparations
- ATRA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IVVD Health Care
- ATRA Health Care
- Exchange
- IVVD Nasdaq
- ATRA Nasdaq
- Market Cap
- IVVD 63.4M
- ATRA 67.9M
- IPO Year
- IVVD 2021
- ATRA 2014
- Fundamental
- Price
- IVVD $1.43
- ATRA $12.12
- Analyst Decision
- IVVD Strong Buy
- ATRA Strong Buy
- Analyst Count
- IVVD 4
- ATRA 3
- Target Price
- IVVD $3.64
- ATRA $21.00
- AVG Volume (30 Days)
- IVVD 15.0M
- ATRA 57.1K
- Earning Date
- IVVD 11-13-2025
- ATRA 11-11-2025
- Dividend Yield
- IVVD N/A
- ATRA N/A
- EPS Growth
- IVVD N/A
- ATRA N/A
- EPS
- IVVD N/A
- ATRA 0.56
- Revenue
- IVVD $46,210,000.00
- ATRA $188,667,000.00
- Revenue This Year
- IVVD $385.94
- ATRA N/A
- Revenue Next Year
- IVVD $62.62
- ATRA N/A
- P/E Ratio
- IVVD N/A
- ATRA $21.52
- Revenue Growth
- IVVD 1941.08
- ATRA 202.41
- 52 Week Low
- IVVD $0.35
- ATRA $5.01
- 52 Week High
- IVVD $2.74
- ATRA $18.71
- Technical
- Relative Strength Index (RSI)
- IVVD 72.86
- ATRA 52.72
- Support Level
- IVVD $0.96
- ATRA $11.70
- Resistance Level
- IVVD $1.45
- ATRA $13.20
- Average True Range (ATR)
- IVVD 0.19
- ATRA 0.63
- MACD
- IVVD 0.05
- ATRA -0.11
- Stochastic Oscillator
- IVVD 97.86
- ATRA 28.00
About IVVD Invivyd Inc.
Invivyd Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of antibody-based solutions for infectious diseases with pandemic potential. The company is developing antibodies to transcend the limits of naturally occurring immunity and provide superior protection from viral diseases, beginning with COVID-19. The company's product candidates are; ADG20 developed for the treatment and prevention of coronavirus disease, and VYD222, a monoclonal antibody candidate engineered, optimizing for potency and breadth of coverage, as well as providing a higher probability of retaining its utility for a longer duration in an evolving viral landscape.
About ATRA Atara Biotherapeutics Inc.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).